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Abstract
Background: Continuation of interferon (IFN) β-based therapies is important for maximum treatment effectiveness
in patients with multiple sclerosis (MS); however, few real-world data are available on discontinuation from IFN β.
The aim of this cohort analysis was to estimate real-world discontinuation rates up to 3 years among MS patients in
the United States taking subcutaneous (sc) IFN β-1a three times a week (tiw) and to identify whether the factors
associated with discontinuation change over time.
Methods: Patient data were pooled from the MarketScan© Commercial and Medicare Supplemental healthcare
claims databases. Patients with ≥1 multiple sclerosis diagnosis who were sc IFN β-1a tiw naïve, had ≥1 year of
continuous eligibility before treatment, and ≥1 prescription were followed from first prescription (index date) until
date of discontinuation, switch, or end of observation. Treatment status was analysed at exactly 1, 2 or 3 years after
index. Multivariable models were used to identify drivers of discontinuation.
Results: Data from 5956 patients were included; 2862 patients (48.1%) discontinued therapy. Discontinuation rates
were 36.9% (1 year), 49.5% (2 years) and 55.8% (3 years). A greater proportion of discontinuing patients had poor
adherence (<80% [94.0%] versus ≥80% [51.7%]) or were taking additional medication at follow-up versus the overall
population. Factors independently associated with discontinuation irrespective of time on therapy were increasing
number of magnetic resonance imaging scans (1 year adjusted odds ratio 1.45, 95% confidence interval 1.26–1.67;
2 years 1.18, 1.06–1.32; 3 years 1.20, 1.07–1.34) and adherence <80% versus ≥80% (1 year 180.95, 135.84–241.03;
2 years 135.80, 100.10–184.23; 3 years 174.89, 115.27–265.38). Factors associated only with early discontinuation (at 1 year)
were ≥3 sets of laboratory investigations versus none (2.54, 1.20–5.38), and anxiolytic use at follow-up (1.40, 1.06–1.82).
Factors associated only with later discontinuation (at 2 years and/or at 3 years) were antidepressant use at follow-up
(2 years 1.46, 1.10–1.94) and greater number of relapses (2 years 1.60, 1.11–2.30; 3 years 2.31, 1.27–4.22).
Conclusions: Potential drivers of discontinuation change over time. Improved awareness of the drivers of discontinuation
could lead to targeted interventions to improve adherence.
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Background
The chronic nature of multiple sclerosis (MS) necessi-
tates long-term treatment with a disease-modifying drug
(DMD) to delay the progression of MS-related disability,
reduce the frequency of relapses and prevent the forma-
tion of new brain lesions in patients with the relapsing-
remitting form of the disease [1]. Adherence is defined
as the ability and willingness to follow a prescribed
treatment regimen correctly [2]. Good adherence to
DMDs is essential, as it is associated with better
clinical outcomes, such as reduced use of health care
resources, lower costs, and improvements in patient
quality of life [3–6].
Of the DMDs available for the treatment of MS, inter-
feron (IFN) β-based therapies are some of the most widely
prescribed [7]. Continued treatment with IFN-β therapy is
important to achieve maximum treatment efficacy, [8] but
data from clinical trials and registries show that IFN-β
therapies have a treatment discontinuation rate of
between 14 and 44%, which may lead to disease reactiva-
tion [9]. The causes of IFN-β discontinuation may also
change as a function of time. A retrospective hospital-
chart-based study recently showed a clear difference in
stopping patterns of IFN-β therapy according to the
length of time on treatment, with patients stopping IFN-β
therapy due to side effects after a median of 13 months,
while those discontinuing due to failure of therapy
stopped after a median of 36 months [10].
The aim of this cohort analysis was to estimate IFN-β
discontinuation rates among MS patients in the United
States (US) receiving subcutaneous (sc) IFN β-1a three
times a week (tiw), and to identify factors associated
with stopping patterns according to time on treatment in
a real-world setting, by using data from claims databases.
This analysis has the potential to provide insights on po-
tential strategies to improve medication-taking behaviour
and help health care providers anticipate how the chal-




Data were pooled from two sources. The first was the
longitudinal Truven MarketScan© Commercial Claims
and Encounters database, which contains claims for
more than 138 million health plan members from the
year 2000 onwards and is considered to be representa-
tive of the US commercially insured population. The
second source was the Medicare Supplemental and
Coordination of Benefits (Medicare) databases, which
contain the pooled claims data of approximately 2.5
million claimers in the US annually who have Medicare
Supplemental Insurance paid for by employers.
Patients
Patient data were included in the retrospective analysis
if patients were ≥18 years old on the year of the index
date, had a diagnosis of MS (presence of ≥1 medical
claim with a primary or secondary International Classifi-
cation of Diseases, 9th revision, Clinical Modification
[ICD-9-CM] diagnosis code for MS [340]) and had initi-
ated treatment with sc IFN β-1a tiw during the study
period (January 1, 2007 to December 31, 2013), had no
record of previous sc IFN β-1a tiw treatment recorded
in the database for at least 1 year before the index date,
had ≥1 pharmacy claim for sc IFN β-1a tiw after the
index date (captured through National Drug Codes), and
had ≥1 year of continuous eligibility of treatment initi-
ation with sc IFN β-1a tiw. Patients with a prescription
for sc IFN β-1a tiw without a recorded diagnosis code
for MS were excluded, as were pregnant women.
Patients were followed from first prescription for sc IFN
β-1a tiw until therapy switch or discontinuation, end of
insurance eligibility, or end of observation period,
whichever occurred first.
Data were fully compliant with the Health Insurance
Portability and Accountability Act of 1996 (HIPPA).
Given that the study only involved de-identified data,
Institutional Review Board review or approval was not
required.
Study measures
Patient demographics were captured at the time of the
index prescription claim, with baseline characteristics
based on the year preceding sc IFN β-1a tiw initiation
(baseline period). Health care utilisation, adherence,
persistence, sc IFN β-1a tiw treatment duration, and use
of corticosteroids and other symptomatic therapies were
measured during follow-up (≥1 prescription fill), includ-
ing the index date.
Annualised relapse rates were calculated using a
validated algorithm [11, 12] that defined an MS-related
relapse as a claim in the primary position at any time
during an in-patient hospitalisation, or a claim with an
MS diagnosis code in the primary or secondary
outpatient setting (including emergency room visits) in
addition to a pharmacy or medical claim for a qualifying
corticosteroid on the day of, or within 7 days after, the
visit. Comorbidity burden was evaluated using the
Charlson Comorbidity Index score [13].
Treatment adherence was operationalised as the num-
ber of days of medication supplied within a refill interval
in relation to the number of days in the refill interval,
also referred to as the medication possession ratio [14].
Treatment persistence was defined as the proportion of
patients who continued on sc IFN β-1a tiw for a period
of 1 year without a gap in therapy of ≥90 days, [15] and
treatment duration was calculated as the time (in
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months) elapsed from index date to switch or complete
discontinuation.
Statistical analysis
All statistical analyses were performed using SAS 9.4
(SAS institute Inc., Cary, NC, USA). Frequency distribu-
tions for categorical variables and mean (standard
deviation) or median (interquartile range [IQR]) for
continuous variables were calculated.
Overall discontinuation (%) was measured using the
total sample of patients and with variable follow-up
time. Discontinuation at 1 year, 2 years, and 3 years was
calculated using patients who were followed-up for at
least 1, 2, and 3 years, respectively. The proportion of
patients who discontinued, including those who
switched to another drug after discontinuation, at 1 year,
2 years and 3 years was calculated for patients who were
followed-up for at least 1, 2 and 3 years, respectively.
Among patients who continued or discontinued, the
mean (standard deviation [SD]) number of relapses per
year and the proportion of patients with a high number
of relapses was calculated for the patients who were
followed-up for at least 1, 2 and 3 years respectively.
To identify potential factors associated with discon-
tinuation, bivariate and multivariate logistic regression
models were used, and results were expressed as odds
ratios (OR) with 95% confidence interval (CI). Variables
with an unadjusted OR at the 0.15 level were included in
the initial multivariable model and a stepwise fitted
procedure was used; a variable was retained in the model
if the p value was <0.05. Kaplan-Meier curves were used
to estimate time to discontinuation by relapsing activity
for those with ≥2 sc IFN β-1a claims. The models were
also run without adherence to examine the relationship
of other independent variables with adherence.
Results
Patient characteristics
Overall, data from 5956 patients were included in this
retrospective cohort analysis (Fig. 1). Baseline demo-
graphics and clinical characteristics are shown in
Table 1. Most patients received specialist neurological
care, rather than general or emergency medical care
(Additional file 1: Table S1).
Discontinuation of sc IFN β-1a tiw
In total, 2862 patients (48.1%) discontinued sc IFN β-1a
tiw; the median treatment duration was 6 months
(Table 1). The clinical characteristics of the patients who
discontinued were similar to those reported for the total
sample, although a greater proportion of discontinuing
patients presented with low adherence (adherence <80%,
94.0% versus 51.7%, respectively). In addition, a greater
proportion were taking additional medication at follow-
up versus the overall population (non-steroidal anti-
inflammatory drugs, 65.1% versus 54.1%; antidepres-
sants, 58.8% versus 50.7%; anxiolytics, 26.3% versus
20.6%; corticosteroids, 47.6% versus 37.3%) (Table 1).
The discontinuation rates at 1, 2 and 3 years were
36.9% (1470 of 3975 patients)), 49.5% (1282 of 2592
patients), and 55.8% (928 of 1664 patients), respectively.
Among those who discontinued, 20.6% did not switch to
another drug at 1 year, 22.9% at 2 years, and 23.9% at
3 years. The proportion who discontinued and switched
to another drug was 16.4% at 1 year, 26.6% at 2 years,
and 31.9% at 3 years.
Factors associated with sc IFN β-1a tiw discontinuation
Factors independently associated with sc IFN β-1a tiw
discontinuation at 1 year, 2 years, and 3 years are
summarised in Table 2 and Additional file 1: Table S2.
Two factors were identified that were independently
associated with discontinuation irrespective of time on
therapy. The first was increasing number of magnetic
Fig. 1 Patient flow selection. ICD-9, International Classification of
Diseases, Revision 9. MS, multiple sclerosis. sc IFN β-1a tiw, subcutaneous
interferon beta-1a three times a week. Numbers in brackets are the
proportion of original patients
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resonance imaging (MRI) scans (per one additional
scan), with adjusted OR (AORs) at 1, 2 and 3 years of
1.45 (95% confidence interval [CI] 1.26–1.67), 1.18 (95%
CI 1.06–1.32) and 1.20 (95% CI 1.07–1.34), respectively;
the second was adherence <80% versus adherence ≥80%,
with AORs at 1, 2 and 3 years of 180.95 (95% CI
135.84–241.03), 135.80 (95% CI 100.10–184.23), and
174.89 (95% CI 115.27–265.38), respectively.
Factors associated only with early discontinuation (at
1 year) were three or more sets of laboratory investi-
gations versus no laboratory investigations (AOR 2.54,
95% CI 1.20–5.38) and anxiolytic use at follow-up
(AOR 1.40, 95% CI 1.06–1.82). Factors associated only
with later discontinuation (at 2 years and/or at
3 years) were antidepressant use at follow up versus
no antidepressant use (AOR at 2 years 1.46, 95% CI
1.10–1.94) and a greater number of relapses (AOR at
2 years 1.60, 95% CI 1.11–2.30; AOR at 3 years 2.31,
95% CI 1.27–4.22). Results from multivariable regres-
sion when adherence was removed from the model
are shown in Additional file 1: Table S3.
At 1, 2, and 3 years, patients who had ≥1 relapse were
more likely to discontinue sc IFN β-1a tiw than those
who had no relapses (Fig. 2a–c); at each time point,
those who discontinued had a high mean number of
relapses per year (≥2 relapses) in the year prior to start-
ing treatment with sc IFN β-1a tiw than those patients
who continued (Table 3).
Discussion
In this retrospective cohort study, discontinuation rates
among US patients with MS receiving sc IFN β-1a tiw
increased over time, from 36.9% at the first year to
55.8% at 3 years after treatment initiation. Poor adher-
ence was the main factor associated with discontinuation
of this therapy, irrespective of the length of time on
treatment. The discontinuation rates seen in the current
study are in agreement with those reported previ-
ously,[16] although other studies report a wide variation
in discontinuation in patients with MS. In a respective
cohort study of pharmacy claims in Germany, at 2 years
post-initiation, overall persistence to one of the four
first-line injected therapies was 32.3%, [17] while in a
similar study approximately half of patients with MS had
discontinued DMDs at the same time point [18].
Treatment adherence describes the successful self-
administration of medicine by a patient, taking into
account correct treatment usage with regard to adminis-
tration schedule and treatment regimen (compliance)
over time (persistence) [6]. Poor adherence is a common
problem among patients with many types of chronic
disease, including MS, and improvements in treatment
adherence may have a larger effect on society and health
than most therapeutic advances [2, 19]. Many factors
that contribute to poor adherence to long-term therapy
in patients with MS are recognised; [6] indeed, recent
retrospective [7, 20] and prospective [19] observational
studies indicate that the most common reasons to
discontinue IFN-β therapy in real-world settings are
adverse events (such as influenza-like symptoms, depres-
sion and injection-site reactions) and increased disease
activity (including radiographic progression, relapses,
and disability progression). Although in this study
indices of disability progression were not reported, an
association between relapses and discontinuation was
Table 1 Demographic and clinical characteristics of patients
with multiple sclerosis initiating subcutaneous interferon β-1a,
three times weekly, by discontinuation status





n % n %
Female sex 4447 74.7 2177 76.1
Age, mean (SD) years 44 (10.7) 44 (10.8)
Region
Northeast 999 16.8 481 16.8
North Central 1764 29.6 766 26.8
South 2156 36.2 1066 37.2
West 968 16.3 517 18.1
Unknown 69 1.2 32 1.1
Charlson comorbidity index
Index = 0 3974 66.7 1887 65.9
Index = 1 1102 18.5 552 19.3
Index = 2 501 8.4 242 8.5
Index≥ 3 379 6.4 181 6.3
Relapse per year, mean (SD) 0.21 (0.57) 0.25 (0.55)
High relapse (≥2 relapses)a 271 4.6 154 5.4
DMD use history 2162 36.3 1143 39.9
Treatment duration, median
(IQR) months
9 (3–22) 6 (2–15)
Persistence 5634 94.6 2645 92.4
Adherence to treatment
<80% (vs. ≥80%)
3078 51.7 2691 94.0
Baseline corticosteroid use 2384 40.0 1194 41.7
Follow-up
NSAID use 3221 54.1 1862 65.1
Antidepressant use 3020 50.7 1682 58.8
Anxiolytic use 1229 20.6 753 26.3
Corticosteroid use 2222 37.3 1362 47.6
DMD disease-modifying drug, NSAID non-steroidal anti-inflammatory drugs, IFN
interferon, IQR, interquartile range, SC subcutaneous, SD standard deviation,
Tiw three times a week
aHigh relapse activity defined as having ≥2 relapses in the first year prior to
start of subcutaneous interferon β-1a, three times weekly
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observed at years 2 and 3, and the association with an
increasing number of MRI scans may be an indicator of
radiographic progression. Despite the development of
strategies to help mitigate these factors, [10, 21]
sustained adherence to DMDs in patients with MS
remains low [16, 18].
When we compared factors associated with discontinu-
ation in models including and excluding adherence, the
only variable associated in both models was the number
of laboratory investigations at 1 year (one laboratory in-
vestigation versus no laboratory investigations was in-
versely associated with discontinuation in the model
Table 2 Adjusted odds ratios of factors associated with discontinuation of subcutaneous interferon β-1a, three times weekly, at 1, 2,
and 3 years, respectively
Adjusted odds ratio
(95% confidence interval)
sc IFN β-1a tiw
Discontinuation at
1 year (n = 3975)
Discontinuation at
2 years (n = 2592)
Discontinuation at
3 years (n = 1664)
Female sex (vs. male) NS NS 1.48 (0.98–2.22)
Region (vs. unknown) NS NS NS
Age in years (continuous) NS NS NS
Charlson comorbidity index (≥1 vs. 0) NS NS NS
Relapses per year (continuous) NS 1.60 (1.11–2.30) 2.31 (1.27–4.22)
High relapses (≥2 relapses) (vs. no)a NS NS NS
DMD use history (vs. no) NS NS NS
Months of treatment duration (continuous) NS NS NS
No persistence (vs. yes) NS NS NS
Adherence <80% (vs. ≥80%) 180.95 (135.84–241.03) 135.80 (100.10–184.23) 174.90 (115.27–265.38)
Health resource usage
Hospital visits (1 vs. 0, 2 vs. 0, and ≥3vs. 0) NS NS NS
Emergency room visits 1 vs. 0, 2 vs. 0, and ≥3vs. 0) NS NS NS
Nurse visits (1 vs. 0, 2 vs. 0, and ≥3vs. 0) NS NS NS
Neurologist visits (vs. 10+)
1 0.84 (0.57–1.25) NS NS
2 0.67 (0.47–0.97) NS NS
3+ 1.11 (0.84–1.48) NS NS
Psychologist visits (1 vs. 0, 2 vs. 0, and ≥3vs. 0) NS NS NS
Psychiatrist visits (1 vs. 0, 2 vs. 0, and ≥3vs. 0) NS NS NS
Speech Therapy visits (1 vs. 0, 2 vs. 0, and ≥3vs. 0) NS NS NS
Outpatients (1 vs. 0, 2 vs. 0, and ≥3vs. 0) NS NS NS
Increasing number of MRI scans (one additional scan
versus no increase in number of MRI scans)
1.45 (1.26–1.67) 1.18 (1.06–1.32) 1.20 (1.07–1.34)
Laboratory investigations (vs. 0)
1 0.61 (0.30–1.25) NS NS
2 0.93 (0.38–2.26) NS NS
3+ 2.54 (1.20–5.38) NS NS
Baseline corticosteroid use (No = 0, Yes = 1) NS NS NS
Follow-up
NSAID use (vs. no) NS NS NS
Antidepressants use (vs. no) NS 1.46 (1.10–1.94) NS
Anxiolitics use (vs. no) 1.40 (1.06–1.82) NS NS
Corticosteroid use (vs. no) NS NS NS
DMD disease-modifying drug, IFN interferon, MRI magnetic resonance imaging, NS no significant association with discontinuation, NSAID non-steroidal
anti-inflammatory drug, sc subcutaneous, tiw three times a week
aHigh relapse activity defined as having ≥2 relapses in the first year prior to start of subcutaneous interferon β-1a, three times weekly
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Fig. 2 Kaplan-Meier curves of probability of sc IFN β-1a tiw continuation by follow-up time in days. a Data are truncated at 1 year from the index
date. Kaplan-Meier curves are stratified by the presence of one or more relapses (red line) or no relapses (blue line). 3975 patients were included
in the analysis; 3461 patients had two or more sc IFN β-1a tiw claims during this period. b Data are truncated at 2 years from the index date.
Kaplan-Meier curves are stratified by the presence of one or more relapses (red line) or no relapses (blue line). 2592 patients were included in the
analysis; 2280 patients had two or more sc IFN β-1a tiw claims during this period. c Data are truncated at 3 years from the index date. Kaplan-Meier
curves are stratified by the presence of one or more relapses (red line) or no relapses (blue line). 1664 patients were included in the analysis; 1482
patients had two or more sc IFN β-1a tiw claims during this period
Table 3 Relapse characteristics according to discontinuation status at 1, 2 and 3 years
sc IFN β-1a tiw
Follow-up at 1 year Follow-up at 2 years Follow-up at 3 years
Continued Discontinued Continued Discontinued Continued Discontinued
Total patients, n (%) 2505 (63.0) 1470 (37.0) 1310 (50.5) 1282 (49.5) 736 (44.2) 928 (55.8)
Relapses per year, mean (SD) 0.18 (0.52) 0.32 (0.67) 0.14 (0.34) 0.26 (0.49) 0.12 (0.26) 0.23 (0.42)
Patients with high relapses, n (%)a 97 (3.9) 84 (5.7) 46 (3.5) 73 (5.7) 21 (2.9) 52 (5.6)
IFN, interferon, sc subcutaneous, SD standard deviation, tiw three times a week
aHigh relapse activity defined as having ≥2 relapses in the first year prior to start of subcutaneous interferon β-1a, three times weekly
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without adherence [AOR 0.16]; three or more laboratory
investigations versus no laboratory investigations was as-
sociated with discontinuation in the model that includes
adherence [AOR 2.54]). For the other factors, which were
significantly associated with discontinuation in only one of
the models, we cannot exclude a relationship with adher-
ence. Furthermore, the high AORs for adherence were
driven by the very low proportion of patients who had
adherence ≥80% but still discontinued sc IFN β-1a tiw
(1 year, n = 68; 2 years, n = 66; 3 years, n = 41).
In this retrospective analysis, there was no significant
association between age, sex, and initial DMD, respect-
ively, and discontinuation of sc IFN β-1a tiw, which is in
line with previous studies [22]. Furthermore, although
overall time on treatment was not associated with dis-
continuation, a change was observed in the drivers of
discontinuation as time on therapy increases. In the
short-term (up to and including 1 year), the main drivers
(an increase in laboratory investigations and an increase
in the use of anxiolytics) could be associated with the
common emergent adverse effects of treatment with sc
IFN β-1a tiw [7]. Even though the adverse-event profile
of sc IFN β-1a tiw is well-documented, consistent and
stable during both clinical trials and in real-world ex-
perience, [7] adverse events can still lead to considerable
discomfort and patient anxiety. Pharmacological and
non-pharmacological approaches to prevent discontinu-
ation due to adverse events have not been widely imple-
mented in patients who discontinue sc IFN β-1a tiw
therapy, resulting in missed opportunities to improve
retention [16]. In the long-term (at 2 years and/or at
3 years), factors associated only with later discontinu-
ation were antidepressant use at follow-up versus no
antidepressant use and a greater number of relapses.
Depression and anxiety are both comorbid conditions in
patients with MS, [23] and the presence of both can
contribute to poor adherence to DMDs [24]. Indeed, the
12-month prevalence of depression in patients with MS
has been reported as 25.7%, and estimates of lifetime
prevalence of depression are as high as 50% [25]. MS
patients with comorbid depression are about half as
likely to be adherent to a DMD than MS patients with-
out depression [26]. In addition, in a real-world US
health insurance-claims-based study of more than 8000
patients, depression was also a recognised adverse effect
of treatment with IFN therapy (incidence rate 7.75 [95%
CI 7.32–8.20]) [7]. As the current analysis shows, further
investigation is required to corroborate the validity of
new prescriptions of antidepressants as a driver of
discontinuation at and beyond 2 years, or whether this is
associated with a decrease in quality of life as a conse-
quence of increased disease activity.
The relation between discontinuation and relapse is
not straightforward. The association between the
increase in the number of relapses and later discontinu-
ation (Table 3) could be the result of the absence of per-
ceived benefit of long-term treatment, leading to poor
adherence; however, any theories on the precise nature
of this association require further investigation. Al-
though the exact causes of increased disease activity are
not investigated in this retrospective real-world cohort
study, there are several other possible reasons that could
be investigated further, including the development of
neutralising antibodies, which were shown in a European
prospective multicentre centre study to develop in al-
most a quarter of patients on any IFN β-based regimen
at a median of 23.8 months on treatment. The develop-
ment of neutralising antibodies may abrogate treatment
effectiveness, leading to clinical and radiological disease
progression [27].
The number of patients who discontinued and
switched to a different therapy increased over each of
the time periods studied. Although data on the drugs to
which patients switched was not analysed, the period of
analysis overlaps with the date from which the oral MS
drug dimethyl fumarate first became available in the
USA (March 28, 2013) [28]. This also corresponds to an
increase in market-based reports of dimethyl fumarate
use in the final quarter of 2013 [29]. It is possible that,
in response to the momentum of pre-marketing demand
for an oral therapy, data collected during this study
period may have included patients who switched from
injected to oral therapies. Additionally, the current study
showed that patients who had a history of using other
DMDs may be more likely to switch to another medica-
tion after discontinuing sc IFN β-10 tiw. However, this
period of overlap (9 months) is too short to assess the
impact on discontinuation of sc IFN β-1a tiw.
One limitation of this retrospective study is that, as an
analysis of administrative health care claims data, it does
not take into account all clinical information (such as
MS subtype and disease severity), socioeconomic status,
enrolment in patient-support programmes, and other
factors that might influence discontinuation. However,
claims database analyses may have an advantage over
retrospective chart review for identifying the causes for
discontinuation over time, as they provide a precise
record of the duration of treatment in the broader
patient population and do not have the biases associated
with reporting in clinical trials or post-marketing obser-
vational studies [7].
Conclusion
In conclusion, increased awareness among physicians of
the clinical significance of the length of time on treat-
ment could foster a culture where patients are actively
asked by physicians whether they are experiencing any
time-specific adverse events, rather than reliance on
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emergent or retrospective reporting by patients. Such
improved awareness could lead to earlier access to
disease-management strategies and patient-support ser-
vices and could inform proactive preventive treatment
strategies to improve long-term treatment adherence in
patients with MS.
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